drugset / Trial / NCT04642820
Drugs Brain and Behavior (DDP)
Phase 0
Completed
138 enrolled
University of Chicago
National Institute on Drug Abuse (NIDA) · collab
RandomizedCrossoverQuadruple-blindBasic science
Summary
In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
Timeline
- Start
- 2020-11-01
- Primary completion
- 2023-10-01
- Completion
- 2024-06-01
Outcome
Missed primary endpoint
registry analysis (superiority test); Placebo vs Methamphetamine; p = .05; t-test, 2 sided NCT04642820 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methamphetamine | Small molecule | 20 mg | — |